Key Points. We obsrved excellent outcome of PMBL patients treated with first-line R-CHOP14 and R-ACVBP without radiotherapy.We confirmed the prognostic importan
In a retrospective analysis of 313 PMBL treated in France and Belgium R-CHOP14 and R-ACVBP had excellent 3 yr OS. Although limited by retrospective nature and likely patent selection these regimens performed better than R-CHOP21. R-ACVBP was more toxic than RCHOP. Patients with high pretreatment TMTV had worse outcomes.